Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $300.00 price target. The company has a one-year high of $268.30 and a one-year low of $163.35. Currently, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

MYGN currently has a PEG ratio of 3.61. Another notable valuation metric for BIIB is its P/B ratio of 1.58. The P/B ratio is used to compare a stock's market value with its book value, which is ...

Short BIIB slightly under 174.4, target n/a, stop loss @ 174.9 Check the time stamp on this data. Updated AI-Generated ...

With a solid Zacks Rank and top-tier Value and VGM Style Scores, BIIB should be on investors' short list. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024.

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...